Olymvax Biopharmaceuticals released its 2026 interim report, with net profit attributable to the parent company at negative 32.8726 million yuan, swinging from profit to loss. Total operating revenue was 361 million yuan, up 18.14 percent year on year, marking a second consecutive year of growth. Net cash flow from operating activities was negative 70.4009 million yuan, a decrease of 50.6622 million yuan compared with the same period last year. The company's latest asset-liability ratio was 58.60 percent, up 9.49 percentage points year on year; the latest gross margin was 91.81 percent, down 1.36 percentage points year on year.
Chengdu Olymvax Biopharmaceuticals Inc. ANet loss of 32.87 million yuan, swinging from profit to loss, with negative operating cash flow.